CALLIO THERAPEUTICS
LIVE

Serial Number

99357977

Owner

Callio Operating Co, Inc.

Attorney

Joyce Liou

Filing Date

Aug 26, 2025

Add to watchlist:

No watchlists yet
View on USPTO

CALLIO THERAPEUTICS Trademark

Serial Number: 99357977

CALLIO THERAPEUTICS is a trademark filed by Callio Operating Co, Inc. on August 26, 2025. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Callio Operating Co, Inc. (4 trademarks)

1201 3rd Ave, Suite 2200-124
Seattle, WA 98101

Entity Type: 03

Trademark Details

Filing Date

August 26, 2025

Registration Date

Not Registered

Published for Opposition

July 7, 2026

Goods & Services

Research and development in the fields of pharmaceuticals, biologics, chemistry, protein engineering, proteins and derivatives, antibody-drug conjugates, immunostimulatory antibody-drug conjugates, antibodies with multiple drug or cytokine conjugates, multispecific antibodies, and engineered antibodies, oncology; Providing medical scientific research information in the fields of pharmaceuticals, biologics, chemistry, protein engineering, proteins and derivatives, antibody-drug conjugates, immunostimulatory anti-drug conjugates, antibodies with multiple drug or cytokine conjugates, multispecific antibodies, and engineered antibodies, oncology, and immunology; Drug discovery, custom design, and development services featuring therapeutic agents for the treatment and prevention of diseases; Scientific investigations for medical purposes; Scientific research in the nature of conducting clinical trials for others.

Pharmaceutical and biological preparations for treating cancer; Pharmaceuticals and biological preparations for prophylactic, diagnostic, and therapeutic use in treating, preventing, and managing cancer; Therapeutic agents for medical use, namely, proteins and derivatives, antibody-drug conjugates, immunostimulatory antibody-drug conjugates, antibodies with multiple drug or cytokine conjugates, multispecific antibodies, and engineered antibodies for treating cancer; Pharmaceutical and biological preparations for the prevention, diagnosis and treatment of cancer for clinical, medicinal, therapeutic and diagnostic purposes; Pharmaceutical and biological preparations for use in oncology for treating cancer

Custom manufacturing of pharmaceuticals and therapeutic agents for medical use

Filing History

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 7, 2026 NPUB
PUBLISHED FOR OPPOSITION
Jul 7, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 1, 2026 NONP
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jun 9, 2026 GNEN
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 9, 2026 CNSA
EXAMINER'S AMENDMENT ENTERED
Jun 9, 2026 XAEC
EXAMINERS AMENDMENT E-MAILED
Jun 9, 2026 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jun 9, 2026 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 22, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 21, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 21, 2026 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 21, 2026 GNRN
NON-FINAL ACTION E-MAILED
Jan 21, 2026 GNRT
NON-FINAL ACTION WRITTEN
Jan 21, 2026 CNRT
ASSIGNED TO EXAMINER
Jan 15, 2026 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 14, 2026 NWOS
APPLICATION FILING RECEIPT MAILED
Aug 26, 2025 MAFR
NEW APPLICATION ENTERED
Aug 26, 2025 NWAP